文献速递胸部CT

Lung-RADS 在多元、医疗服务不足的城市肺癌筛查队列中减少假阳性结果的有效性

Effectiveness of Lung-RADS in Reducing False-Positive Results in a Diverse, Underserved, Urban Lung Cancer Screening Cohort.
PubMed 文献 · J Am Coll Radiol · 2018-08-23

本研究在多元、医疗服务不足的城市学术筛查项目中前瞻性应用 Lung-RADS 对低剂量 CT 结果评分,纳入 1,181 例患者、2,270 人年随访。Lung-RADS 假阳性率为 10.4%(95%CI 8.8%-12.3%),低于国家肺癌筛查试验的 23.3%。各分类肺癌率随分级升高而升高,肺癌死亡率为 40% 而其余队列为 2.5%(P < .001)。

要点

  • Lung-RADS 假阳性率 10.4%(95%CI 8.8%-12.3%),低于国家肺癌筛查试验的 23.3%。
  • 基线 Lung-RADS 1 肺癌率 0.2%,2 为 0.5%,3 为 3.4%,4a 为 43%,4b 为 83%。
  • 肺癌患者死亡率 40% vs 其余队列 2.5%(P < .001);54% 患者首次年度检查逾期。

核心结论

  • 在多元且医疗服务不足的城市人群中,使用 Lung-RADS 进行肺癌筛查可有效降低假阳性率(Lung-RADS 10.4% vs 国家肺癌筛查试验 23.3%)。

研究设计与样本

  • 研究经机构审查委员会批准,为临床肺癌筛查队列,低剂量 CT 结果前瞻性赋予 Lung-RADS 或等效评分,共 1,181 例患者、2,270 人年随访,时间自 2012 年 12 月至 2016 年 12 月。

关键影像表现/征象

  • 基线 CT 结果阴性者占 87%(n = 1,031),其中 Lung-RADS 1 的肺癌率为 0.2%,Lung-RADS 2 的肺癌率为 0.5%。
  • 基线阳性检查中 Lung-RADS 3 占 10%(n = 119),4a 占 1.2%(n = 14),4b 占 1.5%(n = 18)。
  • Lung-RADS 3、4a、4b 对应的肺癌率分别为 3.4%、43%、83%。

诊断标准与关键数值

  • Lung-RADS 假阳性率为 10.4%(95%CI 8.8%-12.3%)。
  • 肺癌患病率为 2.1%。
  • 肺癌患者死亡率为 40%,其余队列死亡率为 2.5%(P < .001)。

临床应用与阅片要点

  • 84% 患者(n = 989)通过电子记录或个人联系确认随访,其余通过国家死亡索引确认生命状态。
  • 54% 患者首次年度检查逾期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The Lung CT Screening Reporting and Data SystemTM (Lung-RADSTM) was created to standardize lung cancer screening CT reporting and recommendations but has not been well validated prospectively in clinical practice. The aim of this study was to determine the effectiveness of lung cancer screening using Lung-RADS in a diverse, underserved, academic clinical screening program, focusing on whether Lung-RADS would successfully reduce the 23.3% false-positive rate found in the National Lung Screening Trial.

METHODS: Institutional review board approval was obtained to study the clinical lung cancer screening cohort. Low-dose CT results were prospectively assigned a Lung-RADS or equivalent score. The proportion of examinations in each Lung-RADS category and the corresponding lung cancer rate, subsequent imaging, interventions, mortality, and compliance were tracked. The National Death Index was queried for follow-up losses.

RESULTS: The cohort comprised 1,181 patients with 2,270 person-years of follow-up from December 2012 to December 2016. The mean age was 64 ± 16.2 years, with 51% women, 63% nonwhite, 71% current smokers, 69% overweight and obese, and multiple comorbidities. The Lung-RADS false-positive rate was 10.4% (95% confidence interval, 8.8%-12.3%). Baseline CT results were negative in 87% (n = 1,031): for Lung-RADS 1, the lung cancer rate was 0.2%, and for Lung-RADS 2, the cancer rate was 0.5%. Positive baseline examinations were Lung-RADS 3 in 10% (n = 119), 4a in 1.2% (n = 14), and 4b in 1.5% (n = 18). Corresponding cancer rates were 3.4%, 43%, and 83%, respectively. Lung cancer prevalence was 2.1%. Mortality was 40% in patients with lung cancer versus 2.5% in the remaining cohort (P < .001). Fifty-four percent of patients were overdue for first annual examinations. Eighty-four percent of patients (n = 989) had follow-up verified via electronic records or personal contact, and the remainder had vital status ascertained via the National Death Index.

CONCLUSIONS: Lung cancer screening using Lung-RADS was effective in reducing the false-positive rate compared with the National Lung Screening Trial in a diverse and underserved urban population.

来源:J Am Coll Radiol,查看原文。版权归原作者所有。

引用

  1. Kaminetzky M, Milch HS, Shmukler A, et al. Effectiveness of Lung-RADS in Reducing False-Positive Results in a Diverse, Underserved, Urban Lung Cancer Screening Cohort. J Am Coll Radiol. 2018. PMID: 30146484. doi:10.1016/j.jacr.2018.07.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。